See more : Sunil Healthcare Limited (SUNLOC.BO) Income Statement Analysis – Financial Results
Complete financial analysis of C&F Financial Corporation (CFFI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of C&F Financial Corporation, a leading company in the Banks – Regional industry within the Financial Services sector.
- SportsTek Acquisition Corp. (SPTKU) Income Statement Analysis – Financial Results
- Stora Enso Oyj (STEAV.HE) Income Statement Analysis – Financial Results
- I.C.P. Israel Citrus Plantations Ltd. (CTPL1.TA) Income Statement Analysis – Financial Results
- Innofactor Oyj (IFA1V.HE) Income Statement Analysis – Financial Results
- Dongfeng Motor Group Company Limited (0489.HK) Income Statement Analysis – Financial Results
C&F Financial Corporation (CFFI)
About C&F Financial Corporation
C&F Financial Corporation operates as a bank holding company for Citizens and Farmers Bank that provides banking services to individuals and businesses. The company's Retail Banking offers various banking services, including checking and savings deposit accounts, as well as business, real estate, development, mortgage, home equity, and installment loans. It also provides ATMs, Internet and mobile banking, and debit and credit cards, as well as safe deposit box rentals, notary public, electronic transfer, and other customary bank services. This segment offers its services through its main office in West Point, Virginia, as well as through 30 Virginia branches located 1 each in Albermarle, Goochland, Hanover, Middlesex, Powhatan, Stafford, York, Charlottesville, Hampton, Montross, Newport News, Richmond, Warsaw, and Williamsburg; 2 each in the counties of Cumberland, James City, King George, and New Kent; and four each in the counties of Chesterfield and Henrico. The company's Mortgage Banking segment provides various residential mortgage loans; originates conventional mortgage loans, mortgage loans insured by the Federal Housing Administration, and mortgage loans guaranteed by the United States Department of Agriculture and the Veterans Administration; and ancillary mortgage loan origination services for residential appraisals, as well as various mortgage origination functions to third parties. It provides mortgage loan origination services through 11 offices in Virginia, 1 office in Maryland, and 2 offices in North Carolina, as well as through 1 each in South Carolina and West Virginia. The company's Consumer Finance segment provides automobile loans through its offices in Richmond and Hampton, Virginia. It also offers brokerage and wealth management services; and insurance products. In addition, the company provides title and settlement agency, and insurance services. C&F Financial Corporation was founded in 1927 and is headquartered in West Point, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 119.05M | 1.68M | 134.53M | 138.95M | 112.47M | 107.28M | 106.73M | 106.10M | 99.07M | 97.31M | 93.81M | 100.36M | 88.96M | 86.31M | 86.20M | 67.88M | 67.33M | 67.51M | 64.36M | 57.98M | 59.16M | 42.89M | 33.67M | 24.06M | 25.90M | 24.10M | 18.50M | 4.71M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 47.20M | 42.00M | 43.10M | 41.93M | 38.93M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.79M | 28.00B | 21.41B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 119.05M | 1.68M | 134.53M | 138.95M | 65.27M | 65.28M | 63.63M | 64.17M | 60.14M | 97.31M | 93.81M | 100.36M | 88.96M | 86.31M | 86.20M | 67.88M | 67.33M | 67.51M | 64.36M | 29.19M | -27.95B | -21.36B | 33.67M | 24.06M | 25.90M | 24.10M | 18.50M | 4.71M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 58.03% | 60.85% | 59.61% | 60.48% | 60.71% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 50.35% | -47,236.70% | -49,811.01% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 56.54M | 47.87M | 58.58M | 57.67M | 47.20M | 42.00M | 43.10M | 41.93M | 38.93M | 36.07M | 31.17M | 40.69M | 34.32M | 34.89M | 35.12M | 27.72M | 30.79M | 29.01M | 28.28M | 25.23M | 24.41M | 18.04M | 13.44M | 9.60M | 9.40M | 8.30M | 6.30M | 5.97M |
| Selling & Marketing | 1.55M | 1.81M | 1.52M | 1.66M | 1.78M | 1.60M | 1.52M | 1.63M | 1.41M | 1.33M | 964.00K | 813.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 79.70M | 47.87M | 58.58M | 57.67M | 47.20M | 42.00M | 43.10M | 41.93M | 38.93M | 36.07M | 31.17M | 40.69M | 34.32M | 34.89M | 35.12M | 27.72M | 30.79M | 29.01M | 28.28M | 25.23M | 24.41M | 18.04M | 13.44M | 9.60M | 9.40M | 8.30M | 6.30M | 5.97M |
| Other Expenses | 0.00 | -4.91M | -155.03M | -167.40M | -135.74M | -127.33M | 98.37M | 97.15M | 90.38M | -108.01M | -95.24M | -106.91M | -92.68M | -96.91M | -98.39M | -69.42M | -62.91M | -60.50M | -63.67M | 0.00 | 0.00 | 0.00 | -23.82M | -14.69M | -17.00M | -14.30M | -10.30M | 2.01M |
| Operating Expenses | 79.70M | 42.96M | -96.45M | -109.73M | -88.53M | -73.71M | 98.37M | 97.15M | 90.38M | -71.94M | -64.07M | -66.22M | -58.36M | -62.02M | -63.27M | -41.69M | -32.12M | -31.50M | -35.39M | -12.64M | -18.65B | -12.24B | -10.38M | -5.09M | -7.60M | -6.00M | -4.00M | 7.98M |
| Cost & Expenses | 79.70M | 42.96M | -96.45M | -109.73M | -88.53M | -73.71M | 141.47M | 139.07M | 129.31M | -236.00K | -64.07M | -66.22M | -58.36M | -62.02M | -63.27M | -41.69M | -32.12M | -31.50M | -35.39M | 16.15M | 9.35B | 9.17B | -10.38M | -5.09M | -7.60M | -6.00M | -4.00M | 7.98M |
| Interest Income | 124.14M | 101.35M | 93.73M | 96.91M | 95.01M | 92.55M | 89.59M | 89.44M | 87.05M | 86.50M | 80.21M | 76.96M | 73.79M | 69.85M | 64.97M | 64.13M | 64.83M | 58.58M | 48.77M | 40.84M | 38.67M | 30.62M | 28.23M | 26.42M | 23.70M | 22.70M | 19.80M | 18.33M |
| Interest Expense | 26.43M | 7.89M | 8.36M | 13.38M | 14.56M | 11.03M | 9.60M | 8.97M | 8.69M | 8.53M | 8.62M | 10.11M | 11.88M | 13.24M | 15.46M | 21.40M | 23.38M | 18.46M | 12.00M | 7.55M | 8.83M | 9.18M | 11.98M | 11.31M | 9.10M | 9.60M | 8.00M | 7.67M |
| Depreciation & Amortization | 3.88M | 4.36M | 4.74M | 4.19M | 3.87M | 3.67M | 3.45M | 3.31M | 2.51M | 2.74M | 2.35M | 2.27M | 2.12M | 1.89M | 2.07M | 2.44M | 2.56M | 2.01M | 1.55M | 1.45M | 1.69M | 1.74M | 1.60M | 1.29M | 1.20M | 1.20M | 1.20M | 1.14M |
| EBITDA | 0.00 | 41.32M | 42.82M | 33.41M | 27.80M | 118.31M | 0.00 | 0.00 | 0.00 | 0.00 | 23.46M | 26.30M | 20.83M | 12.95M | 14.68M | 0.00 | 14.39M | 19.57M | 18.52M | 24.69M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Ratio | 0.00% | 2,913.20% | 31.83% | 24.04% | 24.72% | 34.71% | 28.49% | 27.77% | 28.86% | 29.12% | 34.20% | 36.28% | 36.77% | 30.33% | 29.00% | 42.17% | 56.09% | 56.32% | 47.42% | 43.46% | 50.31% | 57.88% | 73.94% | 84.22% | 75.29% | 80.08% | 84.86% | 293.70% |
| Operating Income | 39.35M | 44.64M | 38.08M | 29.22M | 23.93M | 33.57M | 116.33M | 115.07M | 107.76M | 25.60M | 29.74M | 34.14M | 30.59M | 24.29M | 22.93M | 26.19M | 35.20M | 36.02M | 28.97M | 24.69M | 29.32B | 21.45B | 23.29M | 18.97M | 18.30M | 18.10M | 14.50M | 12.69M |
| Operating Income Ratio | 33.05% | 2,654.22% | 28.31% | 21.03% | 21.28% | 31.29% | 109.00% | 108.45% | 108.78% | 26.31% | 31.70% | 34.02% | 34.39% | 28.15% | 26.60% | 38.58% | 52.29% | 53.35% | 45.01% | 42.58% | 49,556.38% | 50,020.00% | 69.17% | 78.85% | 70.66% | 75.10% | 78.38% | 269.44% |
| Total Other Income/Expenses | -10.18M | 0.00 | -281.00K | -2.20M | -22.56M | -23.02M | -98.37M | -97.15M | -90.38M | -315.00K | -2.35M | -2.27M | -2.12M | -1.89M | 0.00 | -1.58M | 0.00 | -2.01M | -1.55M | -8.49M | -10.07B | -7.55B | -11.98M | -11.31M | -9.10M | -9.60M | -8.00M | -7.67M |
| Income Before Tax | 29.16M | 36.96M | 38.08M | 29.22M | 23.93M | 22.54M | 17.97M | 17.92M | 17.38M | 17.08M | 21.11M | 24.03M | 18.71M | 11.06M | 7.47M | 4.80M | 11.82M | 17.56M | 16.97M | 16.20M | 19.25M | 13.90M | 11.31M | 7.66M | 9.20M | 8.50M | 6.50M | 5.02M |
| Income Before Tax Ratio | 24.50% | 2,197.62% | 28.31% | 21.03% | 21.28% | 21.01% | 16.83% | 16.89% | 17.55% | 17.55% | 22.51% | 23.94% | 21.03% | 12.81% | 8.67% | 7.07% | 17.56% | 26.01% | 26.37% | 27.95% | 32.53% | 32.41% | 33.58% | 31.84% | 35.52% | 35.27% | 35.14% | 106.61% |
| Income Tax Expense | 5.42M | 7.60M | 8.96M | 6.80M | 5.08M | 4.52M | 11.39M | 4.46M | 4.85M | 4.73M | 6.71M | 7.65M | 5.74M | 2.95M | 1.95M | 617.00K | 3.34M | 5.43M | 5.18M | 5.01M | 6.33M | 4.14M | 3.32M | 1.82M | 2.40M | 2.40M | 1.60M | 958.90K |
| Net Income | 23.60M | 29.16M | 28.67M | 22.12M | 18.85M | 18.02M | 6.57M | 13.46M | 12.53M | 12.35M | 14.40M | 16.38M | 12.98M | 8.11M | 5.53M | 4.18M | 8.48M | 12.13M | 11.79M | 11.20M | 12.92M | 9.76M | 7.99M | 5.84M | 6.80M | 6.10M | 4.90M | 4.06M |
| Net Income Ratio | 19.83% | 1,733.59% | 21.31% | 15.92% | 16.76% | 16.80% | 6.16% | 12.69% | 12.65% | 12.69% | 15.35% | 16.32% | 14.59% | 9.40% | 6.41% | 6.16% | 12.60% | 17.97% | 18.32% | 19.31% | 21.84% | 22.77% | 23.73% | 24.26% | 26.25% | 25.31% | 26.49% | 86.24% |
| EPS | 6.92 | 8.29 | 7.95 | 6.06 | 5.47 | 5.15 | 1.89 | 3.90 | 3.68 | 3.63 | 4.37 | 5.00 | 3.76 | 2.26 | 1.44 | 1.38 | 2.79 | 3.85 | 3.49 | 3.14 | 3.58 | 2.73 | 2.25 | 1.62 | 1.83 | 1.59 | 1.25 | 0.92 |
| EPS Diluted | 6.92 | 8.29 | 7.95 | 6.06 | 5.47 | 5.15 | 1.88 | 3.89 | 3.68 | 3.59 | 4.19 | 4.86 | 3.72 | 2.24 | 1.44 | 1.37 | 2.68 | 3.71 | 3.36 | 3.00 | 3.42 | 2.67 | 2.23 | 1.60 | 1.81 | 1.56 | 1.25 | 0.92 |
| Weighted Avg Shares Out | 3.41M | 3.52M | 3.60M | 3.65M | 3.45M | 3.50M | 3.49M | 3.45M | 3.40M | 3.40M | 3.31M | 3.22M | 3.14M | 3.09M | 3.04M | 3.03M | 3.04M | 3.15M | 3.38M | 3.57M | 3.61M | 3.58M | 3.55M | 3.60M | 3.72M | 3.84M | 3.90M | 4.41M |
| Weighted Avg Shares Out (Dil) | 3.41M | 3.52M | 3.60M | 3.65M | 3.45M | 3.50M | 3.49M | 3.46M | 3.40M | 3.44M | 3.44M | 3.31M | 3.17M | 3.10M | 3.05M | 3.06M | 3.16M | 3.27M | 3.51M | 3.73M | 3.78M | 3.66M | 3.58M | 3.65M | 3.76M | 3.91M | 4.41M | 4.41M |
Tyrosine Kinase Inhibitors Market and its Future Outlook and Trend During the Period of 2020 - 2025|Market Research Engine
Biochips Market Research Report with Detailed Analysis 2020 & Forecast to 2026
Global Osteosarcoma Drug Market Growth Study 2020: Key Players are Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc, AstraZeneca, Bristol-Myers Squibb Company
Lung cancer drugs market Analysis By Industry Growth, Size, Share, Demand, Trends and Manufacturers Analysis Research Report
Immunotherapy drugs market Report Analysis, Share, Revenue, Growth Rate With Forecast Overview
Red Biotechnology Market Breakdown Data by Manufacturers, Segments and Regions 2027
Cell Isolation Market to reach USD 9.47 bn by 2024, Agilent Technologies Inc. and Becton, Dickinson and Co. emerge as Key Contributors to Growth| Technavio
Gastrointestinal Cancer Treatment Market Outlook, Opportunity and Demand Analysis Forecast 2020 - 2025
Red Biotechnology Market Outlook 2020 to 2027
Source: https://incomestatements.info
Category: Stock Reports